Experimental ‘Off-the-Shelf’ Cancer Vaccine Is Already Prolonging Lives, Study Suggests
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.